A Study to Compare the Effects of Two Propellants in Adults With Mild Asthma
Status:
Not yet recruiting
Trial end date:
2022-11-01
Target enrollment:
Participant gender:
Summary
This is a Phase IIa, multicentre, single dose, randomised, double blind, controlled, 2 way
cross over study to evaluate the potential for bronchoconstriction of the new HFA-152a
propellant (single dose) versus the marketed HFA-134a propellant (single dose) in adult
subjects with mild asthma.